Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IITerminatedSep 23, 2015Tri-Mix ST3/PGE 2/LIDO 2 0.06/0.2/0.02 InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1795-2015Class IITerminatedSep 23, 2015Tri-Mix ST2/LIDO2/PGE2 0.2/0.1/0.04Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1794-2015Class IITerminatedSep 23, 2015Tri-Mix ST2Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1793-2015Class IITerminatedSep 23, 2015Tri-Mix ST1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1792-2015Class IITerminatedSep 23, 2015Tri-Mix MEDIUMLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1791-2015Class IITerminatedSep 23, 2015Tri-Mix MEDIUMLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1790-2015Class IITerminatedSep 23, 2015Tri-Mix AT-6Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1789-2015Class IITerminatedSep 23, 2015Tri-Mix AT-1Lack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1788-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1787-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1786-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1785-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1784-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1783-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1782-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1781-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1780-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1779-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1778-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1777-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1776-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1775-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1774-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1773-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1772-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1771-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1770-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1769-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1768-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1767-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1766-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1765-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1764-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1763-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1762-2015Class IITerminatedSep 23, 2015Tri-MixLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1761-2015Class IITerminatedSep 23, 2015Testosterone Tri-Blend 200 mg/mlLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1760-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 40 mg/ml InjectableLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1759-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 250 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1758-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 40 mg/mlLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1757-2015Class IITerminatedSep 23, 2015Testosterone Cypionate 220 mg/ml InjectionLack of Assurance of Sterility; FDA inspection identified GMP violations potentially impacting product quality and sterilityThe Compounding Pharmacy of America · D-1756-2015

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.